Drug pricing transparency
Drug pricing transparency in Healthcare & Life Sciences is now a multi-front compliance obligation, not a policy debate. The Centers for Medicare & Medicaid Services has embedded disclosure requirements into hospital and insurer operations through its price transparency final rules, while the Federal Trade Commission has escalated scrutiny of pharmacy benefit manager pricing practices with formal enforcement actions. Compliance teams at manufacturers, PBMs, and health systems are actively auditing their public machine-readable file outputs and vendor arrangements ahead of anticipated FTC rulemaking on PBM transparency.
Watch
- CMS hospital price transparency enforcement: civil monetary penalty increases now active
- FTC PBM 6(b) study findings and potential follow-on rulemaking timeline
- State-level drug pricing boards in California and Colorado issuing binding upper payment limits
- Inflation Reduction Act Medicare drug price negotiation disclosure obligations for manufacturers
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to drug pricing transparency will appear here as they are published.